✦ LIBER ✦

Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond

✍ Scribed by Rebecca H. Ritchie; Jennifer C. Irvine; Anke C. Rosenkranz; Ruchi Patel; Igor R. Wendt; John D. Horowitz; Barbara K. Kemp-Harper

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal antihypertensive therapy for pre

✍ Philip R. Liebson; Rod D. Serry 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 415 KB

Preventing cardiac remodeling: The combi

✍ Suyog A. Mokashi; Jian Guan; Dahai Wang; Vakhtang Tchantchaleishvili; Mark Brigh 📂 Article 📅 2010 🏛 CTSNet 🌐 English ⚖ 360 KB

Cost-effectiveness of losartan-based the

✍ McInnes, G; Burke, T A; Carides, G 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

PCV52 LOSARTAN-BASED VERSUS ATENOLOL-BAS

✍ KJ Krobot; GW Carides; A Wagner; TA Burke 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

An economic assessment of losartan-based

✍ Cornelis Boersma; George W. Carides; Jarir Atthobari; Adriaan A. Voors; Maarten 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 742 KB

MAGNA CARTAThe Great CharterPreamble

📂 Fiction 🌐 English ⚖ 11 KB 👁 18 views